User: Guest  Login
Title:

Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs.

Document type:
Journal Article; Article
Author(s):
Poethko, T; Schottelius, M; Thumshirn, G; Hersel, U; Herz, M; Henriksen, G; Kessler, H; Schwaiger, M; Wester, HJ
Abstract:
Routine application of (18)F-labeled peptides for quantitative in vivo receptor imaging of receptor-expressing tissues and quantification of receptor status using PET is limited by the lack of appropriate radiofluorination methods for routine large-scale synthesis of (18)F-labeled peptides. To satisfy this demand, a new (18)F-labeling methodology based on the chemoselective oxime formation between an unprotected aminooxy-functionalized peptide and an (18)F-labeled aldehyde or ketone was investigated and optimized with respect to peptide conjugation. METHODS: 4-[(18)F]Fluorobenzaldehyde ([(18)F]FB-CHO) was prepared from the 4-formyl-N,N,N-trimethylanilinium precursor via direct no-carrier-added (18)F-fluorination (dimethyl sulfoxide, 60 degrees C, 15 min) and purified using a cation-exchange/reversed-phase cartridge system. Radiochemical yields (RCYs) of N-(4-[(18)F]fluorobenzylidene)oxime ([(18)F]FBOA) formation with various aminooxy-modified peptides such as minigastrin, RGD, and octreotate analogs were investigated as a function of reaction time and temperature, peptide concentration, and pH. Biodistribution studies were performed with an [(18)F]FBOA-RGD dimer ((c(RGDfE)HEG)(2)-K-Dpr-[(18)F]FBOA, 60 and 120 min after injection) and a gylcosylated [(18)F]FB-Tyr(3)-octreotate (Gluc-S-Dpr([(18)F]FBOA)TOCA), 10 and 60 min after injection) using M21 and M21L human melanoma and AR42J rat pancreatic tumor-bearing nude mice, respectively. RESULTS: [(18)F]FB-CHO was obtained in a nonoptimized RCY of 50% within 30 min. At low peptide concentrations (0.5 mmol/L), optimal [(18)F]FBOA-labeling efficiencies (60%-80%) were obtained within 15 min at 60 degrees C and pH 2-3, independently of the peptide used, affording the [(18)F]FBOA-peptides in overall RCYs of up to 40% (from end of bombardment) after purification. Both (c(RGDfE)HEG)(2)-K-Dpr-[(18)F]FBOA and Gluc-S-Dpr([(18)F]FBOA)TOCA showed pharmacokinetics suitable for early (
Journal title abbreviation:
J Nucl Med
Year:
2004
Journal volume:
45
Journal issue:
5
Pages contribution:
892-902
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/15136641
Print-ISSN:
0161-5505
TUM Institution:
Klinik und Poliklinik für Nuklearmedizin
 BibTeX